Released on: September 18, 2008, 1:26 am

Press Release Author: The Scott Partnership

Industry: Biotech

Press Release Summary: Nottingham, UK (17 September 2008). Novozymes Biopharma, part
of Novozymes, world leader in bioinnovation, announces a new development in
animal-free supplements for industrial cell culture on booth #219 at BioProcess
International Conference and Exhibition, 23-26 September 2008, Disneyland Hotel,
Anaheim, CA, USA.

Press Release Body: Novozymes Biopharma Announces New Development in Animal-Free
Cell Culture Supplements at BioProcess International Conference and Exhibition 2008

Nottingham, UK (17 September 2008). Novozymes Biopharma, part of Novozymes, world
leader in bioinnovation, announces a new development in animal-free supplements for
industrial cell culture on booth #219 at BioProcess International Conference and
Exhibition, 23-26 September 2008, Disneyland Hotel, Anaheim, CA, USA.

Novozymes Biopharma, specialists in large scale recombinant protein production for
the biopharmaceutical industry, unveils the first product under the CellPrime brand.
Novozymes' Transferrin recombinant supplement is now commercially ready in scalable
manufacturing quantities for consistency of supply. Designed to reduce risk and ease
regulatory concerns for biopharmaceutical manufacturers, this new advance will
improve the consistency and productivity of customers' industrial cell culture
process.
Manufactured by Novozymes Biopharma, Transferrin is sold exclusively through
Millipore Corporation as part of the CellPrime alliance announced in December 2007.

Novozymes Biopharma will also exhibit its two key product lines, Recombumin and
LONGR3 IGF-I, on booth #219. Recombumin is a yeast derived recombinant human
albumin, which has a structure identical to human serum albumin (HSA).
It is the world's first and only animal-free recombinant human albumin approved for
use in the manufacture of human therapeutics. LONGR3 IGF-I is an analogue of human
insulin-like growth factor I (IGF-I) specifically engineered by Novozymes Biopharma
for use in industrial cell culture. LONGR3 IGF-I provides improved performance and a
consistent, compliant and animal-free alternative to recombinant insulin.

Novozymes Biopharma's portfolio includes biopharmaceutical technologies and
services, contract manufacturing of pharmaceutical grade biological APIs, and
services such as cell banking, technology transfer and process development.

Novozymes Biopharma demonstrates in-depth expertise during the technical conference
with:- . A poster display on "Advances in animal free media supplements for optimal
cell culture performance," presented by Sally Grosvenor, Senior Scientist and
Scientific Communications Manager, Novozymes Biopharma AU Ltd. in the poster area,
Disneyland Hotel, Anaheim.
. A workshop, entitled "Cell Culture and Processing Track" hosted by Sally
Grosvenor, on 25th September 2008 at Magic Kingdom 2 and 3 at 12-12.30pm, will
discuss the ability of two key serum proteins, Transferrin and IGF-I, to stimulate
cell growth and productivity.
. Geoff Francis, Chief Scientist, Novozymes Biopharma AU Ltd is moderator of the
Novozymes sponsored Panel Discussion "Cell Engineering the Future - A Role for Media
Innovation" 12.30pm on 25th September 2008.

To learn more about Novozymes Biopharma's portfolio of products, please visit booth
#219 at BioProcess International Conference and Exhibition 2008.
Alternatively please email Sally
Kent, Marketing Manager, at SYKE@novozymes.com or visit www.biopharma.novozymes.com

About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a
broad array of industries, we create tomorrow's industrial biosolutions, improving
our customers' business and the use of our planet's resources.

With over 700 products used in 130 countries, Novozymes' bioinnovations improve
industrial performance and safeguard the world's resources by offering superior and
sustainable solutions for tomorrow's ever-changing marketplace.

Novozymes' natural solutions enhance and promote everything from removing trans-fats
in food, to advancing biofuels to power the world tomorrow. Our never-ending
exploration of nature's potential is evidenced by over 4,500 patents, showing what
is possible when nature and technology join forces.

Our 4,500+ employees working in research, production and sales around the world are
committed to shaping business today and our world tomorrow.

To arrange a booth meeting with Novozymes Biopharma at BioProcess International 2008
please contact Fiona Robinson, The Scott Partnership on fer@scottpr.com

For further press information please contact: Sally Kent, Marketing
Manager, Novozymes Biopharma UK Ltd. Tel: + 44 115 9551209 or E-mail:
syke@novozymes.com


Web Site: http://

Contact Details: For further press information please contact: Sally Kent, Marketing
Manager, Novozymes Biopharma UK Ltd. Tel: + 44 115 9551209 or E-mail:
syke@novozymes.com